MedElevator Войти в исследования
← Поиск публикаций

DOI 10.7150/thno.125983

Медицинская библиотека · Theranostics · 2026

CAR-T manufacturing reduces heterogeneity between CIDP and multiple myeloma patient-derived T cells.

Wang Xu, Wang Pu, Zhou Qi, Wei Xianzheng, Jin Yuhang, Liao Ying, Zhao Xuan, Hou Rui, Li Sijin, Guan Zhangchun, Ma Wen, Liu Dan, Shi Ming

СтатьяПеревод пока не подготовлен

Аннотация

Rationale:​​ CAR-T cell therapy has demonstrated remarkable promise for managing specific autoimmune disorders. However, it remains unclear, whether long-term immunosuppressive therapy in autoimmune patients adversely affects the phenotype and function of patient-derived CAR-T products. This study aimed to compare the characteristics of T cells and manufactured CAR-T cells from patients with multiple myeloma (MM) and chronic inflammatory demyelinating polyneuropathy (CIDP). ​​

Methods

​​ T cells isolated from MM and CIDP patients, as well as healthy volunteers (for baseline comparisons only), were analyzed. CAR-T cells were generated using an identical manufacturing process. A comprehensive analysis was conducted, including flow cytometry for phenotypic and functional assessment, transcriptomic profiling via RNA sequencing, and in vitro functional assays such as cytokine secretion and cytotoxicity tests. ​​

Results

​​ T cells from CIDP patients showed phenotypes and functional profiles more comparable to those from healthy volunteers. In contrast, MM-derived T cells showed increased CD8⁺ T cell frequency, elevated exhaustion markers, reduced naïve and less-differentiated subsets, and enhanced effector molecule production upon non-specific stimulation. CAR-T manufacturing reduced these inherent differences, yielding similar differentiation states, transcriptomic profiles, and convergent cytotoxic capacities. However, distinct immunomodulatory features persisted, as CIDP-derived CAR-T cells displayed reduced activation markers and lower IFN-γ secretion upon antigen stimulation compared to MM-derived CAR-T cells. ​​

Conclusions

​​ Our study reveals that CAR-T manufacturing process can reduce pre-existing T-cell heterogeneity across different patient populations. These findings support the feasibility of autologous CAR-T therapies in immunosuppressed autoimmune patients, demonstrating that critical cytolytic functions are preserved despite residual alterations in cytokine profiles.

Для цитирования: Wang Xu, Wang Pu, Zhou Qi, Wei Xianzheng, Jin Yuhang, Liao Ying, Zhao Xuan, Hou Rui, Li Sijin, Guan Zhangchun, Ma Wen, Liu Dan, Shi Ming. CAR-T manufacturing reduces heterogeneity between CIDP and multiple myeloma patient-derived T cells.. Theranostics. 2026. DOI: 10.7150/thno.125983.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.